What is Chonluten 20MG

Chonluten 20MG is a bioregulator tripeptide studied in research for its specific affinity and regenerative effects on the respiratory system and lung tissue. It is intended exclusively for research use.

Regarding its chemical identity, Chonluten has a molecular formula of C11H17N3O8 and a molecular weight of 319.27 g/mol. Its reported canonical sequence is Glu-Asp-Gly. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Chonluten.

Product for research use.

Mechanism of action of Chonluten

Chonluten targets the cells of the bronchial mucosa and lung parenchyma. It regulates the synthesis of proteins involved in respiratory function, reduces chronic inflammation, and helps clear accumulated toxins or reactive oxygen species within the pulmonary tract.

Pharmacokinetics and pharmacodynamics of Chonluten

Chonluten has a very rapid half-life in biological media. It acts quickly to modulate gene transcription in pulmonary cells, after which the peptide itself is rapidly degraded into its constituent amino acids.

Scientific evidence on Chonluten

The available evidence on Chonluten is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Research has heavily focused on models of chronic bronchitis, asthma, and recovery from acute respiratory infections. Preclinical evidence suggests it helps restore normal breathing patterns and reduces lung tissue degradation, though human clinical utility remains unconfirmed.

Chonluten applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Chonluten protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Chonluten, so no trial schemes or quantities are specified.

The presentations of this product (20MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Chonluten

As a general guideline for laboratory handling, lyophilized peptides such as Chonluten are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 20MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Chonluten Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Chonluten security profile

The documented safety information in open sources for Chonluten is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Targeting the respiratory system, theoretical risks could include localized tissue reactions if inhaled, though the literature primarily covers its systemic administration in research models without widespread reported adverse events.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Chonluten in a comparative context

Chonluten is unique among the cytogens for its specific pulmonary tropism. Compared to generic anti-inflammatories, it aims to restore cellular function rather than simply masking symptoms.

History and development of Chonluten

Chonluten (sometimes referred to as T-34) was designed as a synthetic analogue of peptides extracted from the respiratory tracts of young animals, specifically targeted to combat respiratory aging and environmental lung damage.